Development of a continuous microbial fermentation system using reduced genome E. coli that undergo programmed autolysis and generate nuclease post-production for the manufacture of biopharmaceuticals

SBIR Phase Phase II award: "Development of a continuous microbial fermentation system using reduced genome E. coli that undergo programmed autolysis and generate nuclease post-production for the manufacture of biopharmaceuticals" awarded to SCARAB GENOMICS LLC in MADISON, Wisconsin. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $937,537. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.